Analysts’ ratings for TScan Therapeutics (NASDAQ:TCRX) over the last quarter vary from bullish to bearish, as provided by 5 analysts. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $12.6, along with a high estimate of $15.00 and a low estimate of $10.00. Highlighting a 1.18% decrease, the current average has fallen from the previous average price target of $12.75. Inter…